{Reference Type}: Journal Article
{Title}: Efficacy and safety of low-dose oral minoxidil in the management of androgenetic alopecia.
{Author}: Gupta AK;Talukder M;Shemer A;
{Journal}: Expert Opin Pharmacother
{Volume}: 25
{Issue}: 2
{Year}: 2024 Feb 5
{Factor}: 4.103
{DOI}: 10.1080/14656566.2024.2314087
{Abstract}: <B>UNASSIGNED: </B>Treating alopecia can be challenging. The available treatments are topical minoxidil, low-dose oral minoxidil (LDOM), and 5-α reductase inhibitors like finasteride and dutasteride. Only topical minoxidil and finasteride 1 mg daily are FDA-approved, while the rest are used off-label. Recent research has suggested that oral minoxidil may be a safe and effective treatment for both female androgenetic alopecia (female AGA) and male androgenetic alopecia (male AGA).<BR><B>UNASSIGNED: </B>In this review, we explore the pharmacokinetics, mechanism of action, safety, and efficacy of oral minoxidil. Additionally, we discuss its effectiveness compared to other treatments available for female AGA and male AGA.<BR><B>UNASSIGNED: </B>LDOM has demonstrated a favorable efficacy and safety profile in several trials. Subsequently, its use for the treatment of male AGA and female AGA is increasing. However, its use remains off-label, and through increased usage, we will get a better idea of the best dosage and monitoring guidelines. LDOM has also been used with some effectiveness in other forms of hair loss.